Physician profile
Shashank Ponugoti
NPI 1205085651
$7,878.16
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $853 · 2020: $402 · 2021: $618 · 2022: $784 · 2023: $4,440 · 2024: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,500 · Food and Beverage: $1,264 · Travel and Lodging: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,500.00 |
| Food and Beverage | $1,263.64 |
| Travel and Lodging | $457.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,806.49 | 2022-2024 | Veklury |
| Janssen Pharmaceuticals, INC | $829.55 | 2019-2022 | |
| Inari Medical, INC. | $578.24 | 2019-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astrazeneca Pharmaceuticals Lp | $436.23 | 2021-2024 | Airsupra |
| Pfizer INC. | $305.84 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $168.99 | 2019-2020 | |
| Abbvie INC. | $160.38 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.26 | 2020 | |
| Alexion Pharmaceuticals, INC. | $120.98 | 2024 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $71.34 | 2019-2020 | |
| Stryker Corporation | $61.43 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.23 | 2022-2023 | Spiriva Respimat |
| Abbott Laboratories | $57.42 | 2024 | Cardiomems |
| Csl Behring | $34.16 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $24.79 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $24.77 | 2019 | |
| Allergan, INC. | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shashank Ponugoti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.